Samsung Biologics, C&T Shares Volatile After Spin-Off Plan

Shares of Samsung Biologics Co. and its largest holder Samsung C&T Corp. were volatile after the Korean contract drug manufacturer announced a spin-off plan.

Investors saw the plan — which will see Samsung Biologics carve its business into a contract drug manufacturer and a holding company that will manage its subsidiaries — as a sign of a bigger restructuring at South Korea’s largest conglomerate.